Narrative synthesis of prescribing pattern literature
Trazodone Prescribing Trends in the United States
How trazodone's role in American medicine has shifted from primarily an antidepressant to predominantly an off-label sleep aid over four decades.
Published August 8, 2026. Reviewed by our editorial team on August 8, 2026.
Who was studied: US outpatient prescriptions, based on published prescribing pattern analyses
One of the more striking, widely discussed patterns in American psychiatric prescribing is how thoroughly trazodone's practical use has diverged from its FDA-approved indication. Clinical commentary and prescribing-pattern research consistently describe the same general trend: most trazodone prescriptions today are written for sleep, not depression, even though depression is the only condition the FDA has formally reviewed and approved it for.
Several factors are generally cited as contributing to this shift: trazodone's lack of controlled-substance scheduling (making it easier to prescribe than some sleep medication alternatives), its low cost as a decades-old generic, and accumulated clinical comfort with its safety profile at low doses. This pattern is a useful case study in how a medication's real-world role can evolve well beyond its original approved purpose through sustained clinical experience.
Main result: Published prescribing pattern analyses and clinical commentary consistently describe a shift over recent decades toward the majority of trazodone prescriptions being written for insomnia rather than depression, even though depression remains its only FDA-approved indication.
Limitations: Exact prescribing proportions vary between different data sources and time periods studied, and this article does not cite a single specific dataset — it summarizes a widely described general trend rather than one study's precise figures.
Not medical advice. This summary is educational and does not replace individualized guidance from your prescriber.
